List of Biosimilars Companies with Phase 2 Active Clinical Trial - 5

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Dr. Reddy's Laboratories is a pharmaceutical company that specializes in pharmaceutical manufacturing and healthcare products.

TRPHARM’s journey, which started in Turkey in 2013, continues with offices in Istanbul and Dubai. Currently, we deliver our products and services to approximately 20 countries, and we maintain our physical presence in 12 of these countries. We are growing rapidly with more than 100 employees who are competent in their fields. We combine our innovative business approaches with medical experience, with the experience of more than a hundred years of experience of the doctors and pharmacists in our team. Our journey that started with medicine continues with the inclusion of non-pharmaceutical health solutions. With our partners in various countries, we provide a wide range of services covering all areas from diagnosis to treatment. Our cooperation philosophy is based on transparency and coexistence within the framework of common goals, guided by our expertise. As TRPHARM, our mission that we have been loyal to since the first day is to bring together innovative solutions with health. Our vision, which we have created with our years of experience, is to be a global, innovative healthcare company. The values that we take as a guide in each of our steps are; LIFE We put people and nature at the heart of our relations with our colleagues, physicians, patients and all other stakeholders and aspire to build a sustainable ecosystem. COLLABORATION In all our actions and business activities, we put harmony, unity and efficiency at the center of our interactions and projects, both within our teams and with our stakeholders. BALANCE In all areas that we add value, we draw on broad vision and harmony of opposite poles/perspectives, and we observe balance and attentiveness in our actions. TRANSFORMATION We adapt to ever-changing conditions that life imposes on us all with resilience and courage. We foresee transformation and changes in needs, respond with agility and grasp new opportunities to achieve our leadership goal.

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.